"Sildenafil Citrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.
Descriptor ID |
D000068677
|
MeSH Number(s) |
D02.065.884.675 D02.886.590.700.675 D03.383.606.854 D03.633.100.759.824
|
Concept/Terms |
Sildenafil Citrate- Sildenafil Citrate
- Citrate, Sildenafil
- 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
UK 92480-10- UK 92480-10
- UK 92480 10
- UK 9248010
- UK-92,480-10
- UK 92,480 10
|
Below are MeSH descriptors whose meaning is more general than "Sildenafil Citrate".
Below are MeSH descriptors whose meaning is more specific than "Sildenafil Citrate".
This graph shows the total number of publications written about "Sildenafil Citrate" by people in this website by year, and whether "Sildenafil Citrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2005 | 0 | 2 | 2 |
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sildenafil Citrate" by people in Profiles.
-
Silver B, McCarthy S, Lu M, Mitsias P, Russman AN, Katramados A, Morris DC, Lewandowski CA, Chopp M. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks. J Stroke Cerebrovasc Dis. 2009 Sep-Oct; 18(5):381-3.
-
McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med. 2008 Feb; 5(2):476-84.
-
Silver B, Grover KM, Arcila X, Mitsias PD, Bowyer SM, Chopp M. Recovery in a patient with locked-in syndrome. Can J Neurol Sci. 2006 May; 33(2):246-9.
-
Copel L, Katz R, Blachar A, Sosna J, Sheiman RG. Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience. Radiology. 2005 Dec; 237(3):986-91.
-
Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med. 2005 Sep; 2(5):658-67.
-
Bedell SE, Graboys TB, Duperval M, Goldberg R. Sildenafil in the cardiologist's office: patients' attitudes and physicians' practices toward discussions about sexual functioning. Cardiology. 2002; 97(2):79-82.
-
Nagata K, Marb?n E, Lawrence JH, Donahue JK. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol. 2001 Mar; 33(3):575-80.
-
Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD, Yood RA. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med. 2000 Dec 11-25; 160(22):3401-5.